Anti-Infliximab (Remsima®) (Human) ELISA Kit

Product Overview

A sandwich ELISA kit for the quantitative measurement of Anti-Infliximab (Remsima®) in Human serum and plasma.

Infliximab (CT-P13) (Remsima®) is a chimeric monoclonal antibody and used to treat auto-immune disorders. Infliximab reduces the amount of active human tumor necrosis factor alpha (hTNFα) in the body by binding to it and preventing it from signaling the receptors for TNFα on the surface of various cell types. Infliximab is used for the treatment of psoriasis, Crohn’s disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis. In controlled trials, clinical response rates of 20-40% have been achieved with above-mentioned regimens in Crohn’s disease and rheumatoid arthritis. However, some patients develop unwanted immunogenicity, which leads to production of anti-drug-antibodies (ADAs) inactivating the therapeutic effects of the treatment and, in rare cases, inducing adverse effects. 96Trace’s BioSimTM anti-Infliximab ELISA kit is designed to quantify/measure the antibody against Infliximab (CT-P13) (Remsima®) with high specificity and sensitivity in biological matrices.

Assay Information

Performance Data

Applications

This ELISA kit is used for quantitative measurement of antibody against Infliximab (Remsima) in human serum and plasma

Features & Benefits

• Designed for quantitative measurement of Anti-Infliximab (Remsima®).
• Assay format: Sandwich ELISA.
• Sample type: Human serum and plasma.
• Detection method: Absorbance (450 nm).
• Detection Range: 62 - 500 ng/ml
• Sensitivity: 30 ng/ml
• Kit size: 96 Well.

Storage & Shipping

Product Details